| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 28,129,866 | 29,757,328 | ||
| Prepaids and other current assets | 3,894,944 | 3,670,319 | ||
| Total current assets | 32,024,810 | 33,427,647 | ||
| Fixed assets, net | 18,068 | 24,908 | ||
| Total assets | 32,042,878 | 33,452,555 | ||
| Accounts payable | 1,111,702 | 931,344 | ||
| Accrued expenses | 1,638,706 | 2,838,685 | ||
| Deferred collaboration revenue | 916,712 | 731,075 | ||
| Total current liabilities | 3,667,120 | 4,501,104 | ||
| Deferred collaboration revenue | 1,091,267 | 641,158 | ||
| Total liabilities | 4,758,387 | 5,142,262 | ||
| Common stock, 0.0001 par value 200,000,000 shares authorized 16,742,638 and 16,707,441 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1,675 | 1,673 | ||
| Additional paid-in capital | 83,537,551 | 82,447,524 | ||
| Accumulated deficit | -56,254,735 | -54,138,904 | ||
| Total stockholders' equity | 27,284,491 | 28,310,293 | ||
| Total liabilities and stockholders' equity | 32,042,878 | 33,452,555 | ||
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)